{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T06:38:55Z","timestamp":1777703935219,"version":"3.51.4"},"reference-count":37,"publisher":"Impact Journals, LLC","issue":"35","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2018,5,8]]},"DOI":"10.18632\/oncotarget.25307","type":"journal-article","created":{"date-parts":[[2018,5,8]],"date-time":"2018-05-08T19:24:41Z","timestamp":1525807481000},"page":"24054-24068","source":"Crossref","is-referenced-by-count":8,"title":["Polymorphisms in the promoter region of the <i>CRBN<\/i> gene as a predictive factor for the first-line CTD therapy in multiple myeloma patients"],"prefix":"10.18632","volume":"9","author":[{"given":"Aneta","family":"Szudy-Szczyrek","sequence":"first","affiliation":[{"name":"Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, 20-081 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rados\u0142aw","family":"Mlak","sequence":"additional","affiliation":[{"name":"Department of Human Physiology, Medical University of Lublin, 20-080 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micha\u0142","family":"Szczyrek","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine in Nursing, Medical University of Lublin, 20-090 Lublin, Poland"},{"name":"Department of Pneumology, Oncology and Allergology, Medical University of Lublin, 20-950 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylwia","family":"Chocholska","sequence":"additional","affiliation":[{"name":"Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, 20-081 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacek","family":"Sompor","sequence":"additional","affiliation":[{"name":"Department of Trauma Surgery and Emergency Medicine, Medical University of Lublin, 20-081 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Nogalski","sequence":"additional","affiliation":[{"name":"Department of Trauma Surgery and Emergency Medicine, Medical University of Lublin, 20-081 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Ma\u0142ecka-Massalska","sequence":"additional","affiliation":[{"name":"Department of Human Physiology, Medical University of Lublin, 20-080 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Hus","sequence":"additional","affiliation":[{"name":"Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, 20-081 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2018,5,8]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Russell","year":"2014","journal-title":"Leukemia"},{"key":"2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Jemal","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"3","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2174\/156800906777441762","article-title":"The use of thalidomide in myeloma therapy as an effective anticancer drug","volume":"6","author":"Joshua","year":"2006","journal-title":"Curr Cancer Drug Targets"},{"key":"4","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1751-553X.2007.00948.x","article-title":"The effects of thalidomide on chemotactic migration of multiple myeloma cell lines","volume":"30","author":"Taniwaki","year":"2008","journal-title":"Int J Lab Hematol"},{"key":"5","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s00018-010-0619-9","article-title":"Teratogenic effects of thalidomide: molecular mechanisms","volume":"68","author":"Handa","year":"2011","journal-title":"Cell Mol Life Sci"},{"key":"6","doi-asserted-by":"publisher","first-page":"23609","DOI":"10.18632\/oncotarget.4603","article-title":"The IMiDs targets IKZF-1\/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma","volume":"6","author":"Cippitelli","year":"2015","journal-title":"Oncotarget"},{"key":"7","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood-2012-06-438101","article-title":"High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance","volume":"121","author":"Sonneveld","year":"2013","journal-title":"Blood"},{"key":"8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.leukres.2013.08.015","article-title":"The clinical significance of cereblon expression in multiple myeloma","volume":"38","author":"Champion","year":"2014","journal-title":"Leuk Res"},{"key":"9","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.critrevonc.2005.01.005","article-title":"Predicting drug response and toxicity based on gene polymorphisms","volume":"54","author":"Bonnet","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"key":"10","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1373\/clinchem.2008.110056","article-title":"A personalized approach to cancer treatment: how biomarkers can help","volume":"54","author":"Crown","year":"2008","journal-title":"Clin Chem"},{"key":"11","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s00018-014-1772-3","article-title":"Prediction of individual response to anticancer therapy: historical and future perspectives","volume":"72","author":"David","year":"2015","journal-title":"Cell Mol Life Sci"},{"key":"12","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3324\/haematol.2011.043372","article-title":"Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results","volume":"97","author":"Ross","year":"2012","journal-title":"Haematologica"},{"key":"13","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.leukres.2010.05.003","article-title":"The efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide, thalidomide, dexamethasone) regimen in patients with multiple myeloma--a report by the Polish Myeloma Study Group","volume":"34","author":"Kloczko","year":"2010","journal-title":"Leuk Res"},{"key":"14","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1182\/blood-2011-02-338665","article-title":"Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation","volume":"118","author":"Drayson","year":"2011","journal-title":"Blood"},{"key":"15","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00277-015-2537-2","article-title":"Phase 3 trial of three thalidomide-containing regimens in patients with newly diagnosed multiple myeloma not transplant-eligible","volume":"95","author":"Chiattone","year":"2016","journal-title":"Ann Hematol"},{"key":"16","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3324\/haematol.11534","article-title":"Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma","volume":"92","author":"Bayssas","year":"2007","journal-title":"Haematologica"},{"key":"17","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1182\/blood-2009-03-201053","article-title":"The role of complete response in multiple myeloma","volume":"114","author":"Avet-Loiseau","year":"2009","journal-title":"Blood"},{"key":"18","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/leu.2008.402","article-title":"Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)","volume":"23","author":"Roussou","year":"2009","journal-title":"Leukemia"},{"key":"19","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/ejh.12407","article-title":"A new staging system to predict prognosis of patients with multiple myeloma in an era of novel therapeutic agents","volume":"94","author":"Tsukamoto","year":"2015","journal-title":"Eur J Haematol"},{"key":"20","doi-asserted-by":"crossref","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","article-title":"Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia 145 Working Party","volume":"23","author":"Drayson","year":"2005","journal-title":"J Clin Oncol"},{"key":"21","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/10428190601126602","article-title":"Renal failure in multiple myeloma: incidence, correlations, and prognostic significance","volume":"48","author":"Dimopoulos","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"22","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Gertz","year":"2008","journal-title":"Blood"},{"key":"23","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1186\/s12885-016-2645-y","article-title":"Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen","volume":"16","author":"Lee","year":"2016","journal-title":"BMC Cancer"},{"key":"24","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Morgan","year":"2005","journal-title":"J Clin Oncol"},{"key":"25","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3324\/haematol.2012.075051","article-title":"Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials","volume":"98","author":"Liberati","year":"2013","journal-title":"Haematologica"},{"key":"26","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1158\/1055-9965.EPI-11-0157","article-title":"Gender disparities in the tumor genetics and clinical outcome of multiple myeloma","volume":"20","author":"Morgan","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"27","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1159\/000357659","article-title":"Thalidomide, cyclophosphamide and dexamethasone induction therapy: feasibility for myeloma patients destined for autologous stem cell transplantation","volume":"132","author":"Kim","year":"2014","journal-title":"Acta Haematol"},{"key":"28","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1634\/theoncologist.2013-0015","article-title":"Influence of body mass index on survival in veterans with multiple myeloma","volume":"18","author":"Carson","year":"2013","journal-title":"Oncologist"},{"key":"29","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Barlogie","year":"1999","journal-title":"N Engl J Med"},{"key":"30","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3816\/CLM.2008.n.041","article-title":"Serum C-reactive protein at diagnosis and response to therapy is the most powerful factor predicting outcome of multiple myeloma treated with thalidomide\/anthracycline-based therapy","volume":"8","author":"Giuliodori","year":"2008","journal-title":"Clin Lymphoma Myeloma"},{"key":"31","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.V98.2.492","article-title":"Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients","volume":"98","author":"Spoon","year":"2001","journal-title":"Blood"},{"key":"32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/09537100903360007","article-title":"Thrombopoietic cytokines and platelet count in multiple myeloma","volume":"21","author":"Haznedar","year":"2010","journal-title":"Platelets"},{"key":"33","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.advms.2013.12.006","article-title":"Does thrombopoiesis in multiple myeloma patients depend on the stage of the disease?","volume":"59","author":"Kemona","year":"2014","journal-title":"Adv Med Sci"},{"key":"34","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s00277-014-2063-7","article-title":"Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma","volume":"93","author":"Chou","year":"2014","journal-title":"Ann Hematol"},{"key":"35","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s00277-016-2743-6","article-title":"Thalidomide-based induction regimens are as effective as bortezomib-based regimens in elderly patients with multiple myeloma with cereblon expression","volume":"95","author":"Lee","year":"2016","journal-title":"Ann Hematol"},{"key":"36","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1182\/blood.V124.21.3628.3628","article-title":"Cereblon (CRBN) Gene polymorphisms predict clinical response and progression-free survival in multiple myeloma patients treated with lenalidomide: a pharmacogenetic study of immense consortium","volume":"124","author":"Zawirska","year":"2014","journal-title":"Blood"},{"key":"37","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00005-016-0442-6","article-title":"Cereblon and IRF4 variants affect risk and response to treatment in multiple myeloma","volume":"64","author":"Bogunia-Kubik","year":"2016","journal-title":"Arch Immunol Ther Exp (Warsz)"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.25307","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T16:51:40Z","timestamp":1589043100000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.25307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,8]]},"references-count":37,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2018,5,8]]}},"alternative-id":["25307","29844872"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.25307","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,8]]}}}